To assess the treatment effect of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration.
We evaluated data from VIEW 1 and VIEW 2, comparing functional and morphologic outcomes at Week 96 between intravitreal aflibercept 2 mg monthly (2q4) or 2 mg bimonthly after 3 initial monthly doses (2q8) versus ranibizumab 0.5 mg monthly among Asian patients (n = 269) and between Asian and white patients (n = 2044).
In Asian patients, there were no significant differences between intravitreal aflibercept 2q4 and 2q8 compared with ranibizumab in mean gain in best-corrected visual acuity (10.23 and 8.35 vs. 8.51 letters). Reduction in central retinal thickness was greater for intravitreal aflibercept 2q4 (150.43 μm, P = 0.0075) and 2q8 (148.15 μm, P = 0.0126) than ranibizumab (119.46 μm). The proportion of dry retinas was greater for intravitreal aflibercept 2q4 (65.7%, P < 0.01) than ranibizumab (41.7%). There were no differences in outcomes between Asian and white patients. Serious treatment-emergent ocular adverse events occurred in <8% of treated eyes, evenly distributed across subgroups.
In Asian patients with neovascular age-related macular degeneration, functional and morphologic outcomes were largely similar between intravitreal aflibercept and ranibizumab groups, and to results seen in white patients.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Post hoc analyses of the Asian subpopulation of the VIEW trials demonstrated that visual and anatomic outcomes were similar in eyes treated with intravitreal aflibercept and ranibizumab, and were similar to outcomes seen in white patients.
*Singapore Eye Research Institute, Singapore National Eye Center, The Academia, Singapore;
†Duke-NUS Graduate Medical School, National University of Singapore, Singapore;
‡Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China;
§Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, People's Republic of China;
¶National Yang-Ming University School of Medicine, Taipei, Taiwan, People's Republic of China;
**Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea;
††Department of Ophthalmology, University of Ulsan, College of Medicine, Ulsan, South Korea;
‡‡Asan Medical Center, Seoul, South Korea;
§§Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan;
¶¶Bayer AG, Berlin, Germany; and
***Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Reprint requests: Tien Yin Wong, MD, PhD, Singapore National Eye Center, 11 Third Hospital Avenue, Singapore 168751; e-mail: email@example.com
The VIEW 1 and VIEW 2 trials were supported by Bayer and Regeneron Pharmaceuticals, Inc.
The study funders had a role in study design, collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the article for publication. Medical writing assistance was provided by Corey Eagan, MPH, of PAREXEL, and was funded by Bayer.
Conflict of interest statement has been moved to acknowledgments section.